...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British journal of cancer >The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
【24h】

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.

机译：聚乙二醇脂质体的临床益处阿霉素在转移性乳腺癌患者癌症之前与常规治疗蒽环霉素:多中心II期临床试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study evaluates the clinical benefit of pegylated liposomal doxorubicin (PLD) in patients with metastatic breast cancer (MBC), previously treated with conventional anthracyclines. Seventy-nine women with MBC previously treated with anthracyclines received PLD 50 mg m(-2) every 4 weeks. All patients were previously treated with chemotherapy and 30% of patients had > or =3 prior chemotherapies for metastatic disease. Patients were considered anthracycline resistant when they had disease progression on anthracycline therapy for MBC or within 6 months of adjuvant therapy. The overall clinical benefit rate (objective response+stable disease > or =24 weeks) was 24% (16.1% in patients with documented anthracycline resistance vs 29% in patients classified as having non-anthracycline-resistant disease). There was no difference with respect to the clinical benefit between patients who received PLD >12 months and those who received PLD or =12 months. In conclusion, PLD was associated with an evident clinical benefit in anthracycline-pretreated patients with MBC.
机译：本研究评估的临床受益聚乙二醇脂质体阿霉素(骑士)的病人与转移性乳腺癌(MBC)与传统蒽环霉素治疗。七十九名女性与MBC以前治疗蒽环霉素收到骑士50毫克m (2)每4周。接受化疗和30%的患者> = 3或化疗前转移疾病。抗疾病进展时蒽环霉素治疗MBC或6个月内辅助治疗。率(客观反应+稳定疾病>或= 24周)为24%(16.1%的患者记录蒽环霉素抗性vs 29%的病人分为有non-anthracycline-resistant疾病)。患者之间的临床益处收到骑士> 12个月,收到的人自去年蒽环霉素骑士或= 12个月。明显的临床受益anthracycline-pretreated MBC患者。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号